Advantages and side effects of tucatinib/tucatinib

Tucatinib/Tucatinib (Tucatinib) is considered a representative "third generation" small molecule drug in HER2-targeted therapy. It is known for its high selectivity, high safety and excellent central nervous system efficacy. Compared with earlier drugs such as lapatinib, tucatinib barely inhibits EGFR and therefore significantly reduces side effects such as rash and severe diarrhea.

One of its biggest advantages is its outstanding effect in the treatment of brain metastases. HER2-positiveBreast cancerAbout50% of patients may develop brain metastasis, and most drugs have difficulty penetrating the blood-brain barrier. The molecular structure of tucatinib has been optimized to effectively enter the central nervous system and significantly reduce the risk of brain metastasis progression. The overseas HER2CLIMB study shows that tucatinib combined with trastuzumab and capecitabine can increase the disease control rate of patients with brain metastases to more than twice that of traditional regimens, becoming a new standard for the treatment of HER2-positive brain metastases.

From the perspective of pharmacological characteristics, tucatinib can inhibitHER2 kinase activity without interfering with EGFR. This selectivity means that patients have a better experience during treatment and a lower discontinuation rate. Its oral dosage form design also improves treatment convenience, reduces dependence on intravenous infusion, and is suitable for long-term maintenance treatment.

In terms of safety, the adverse reactions of tucatinib are generally mild to moderate. Common side effects include diarrhea, nausea, stomatitis, fatigue, and elevated liver enzymes. Individual patients may experience elevated ALT and AST. Therefore, it is recommended to monitor liver function at the beginning of treatment and before each cycle. If there are obvious abnormalities in liver function, doctors can adjust the dose or suspend treatment according to the toxicity grade. Compared with other HER2-targeted drugs, tucatinib's skin and gastrointestinal toxicity is significantly reduced, and patient compliance is higher.

The clinical significance lies not only in prolonging survival, but also in changing the treatment logic of HER2-positive breast cancer from "systemic control" to "precise targeting in the brain".

Reference materials:https://www.tukysa.com/